Dechra Pharmaceuticals Share Discussion Threads

[johnrxx99] 12/1/2023 04:13

Liberum raises Dechra Pharmaceuticals to 'buy'

Alliance News 11/1/2023

[disc0dave45] 11/1/2023 10:21

Could be a trading update tomorrow.

[crabbeng] 14/12/2022 16:12

I'm having a punt

[johnrxx99] 14/12/2022 07:17

We should be so lucky :-)

[crabbeng] 13/12/2022 13:35

Is this starting to wake up?

[steeplejack] 20/9/2022 10:25

Sun Times article (18 Sept)about Ian Page.Reassured by his critical comments on wokish behaviour!No matter where you search for safety,whether it be by buying a Dechra,a Dalgety ,an Astra Zeneca or a Halma,you're going to be hard pressed to make money in these markets.The Wall St Journal notes that with two year US treasuries now yielding around 3.5%,equities are under comparative pressure as the recession bites.Cash remains king.It's all very well the financial press pointing out the deprecation that cash suffers in an inflationary environment but a high level of liquidity seems eminently sensible and preferable to losing money in equities.(Even alternative asset classes like gold are at 2 and half year lows).

[1jat] 07/9/2022 17:53

The long term direction for CAP business is positive as we personify our pets and seek better health for them….”good” owners will still pay up….the question is whether you buy pharma, vets or pet stores….it depends how you see the value being shared along the chain….
My preference is for pharma and vets.

[disc0dave45] 05/9/2022 21:09

WealthOracle just regurgitating what's already out there in the press. Be careful of what this character km posts as clearly works for WO. They beat eps forecasts by 2.4% and if they also beat forecasts by the same amount for FY23, then on a forward PE of 24x not 27.9x. Yes still rated highly but always has been because it's a quality business. It's lowest PE rating over the last 6 years or so has been about 31x (2018), so now trading at a significant discount to that (current PE of 25.8). You pays your money and takes your choice.DYOR

[km18] 05/9/2022 15:04

Dechra Pharmaceuticals Plc posted Prelims for the FY ended 30th June 2022. Revenues grew 13.8% to £681.8 million, reported operating profit rose 16.2% to £95.5m, underlying diluted EPS increased 14.0% to 120.84 pence and the FY dividend increased by 10.8% to 44.89 pence, all at constant exchange rate. The business has been growing solidly for many years now, but valuation remains unhelpful with forward PE ratio at 27.9x and PS ratio at 6.21x. Share price has been in a correction for most of 2022 and this correction has extended another 10%+ following today’s release. DPH is a high quality and solid growth business, but it is expensive and a share to monitor for now...

...from WealthOracle

[steeplejack] 05/9/2022 11:28

We don’t have the research coverage of yesteryear but what intrigues me is that analysts nowadays must be pitifully behind the curve.How on earth can you have such volatility in all things equity if the analysts are on top of their game .Am i to understand that these results massively undershot expectations?Have these results (like so many others) taken our scribblers unaware?In reality,we are simply being tossed on the vagaries of algorithmic trading and flighty proprietary books seeking a quick turn.You could be dealing in apples and pears for knowledge of the company in the short term appears to be secondary in evaluating a company valuation.Increasingly volatile equities are beginning to mimic cryptocurrency dealing I wonder who benefits in this casino. It is a inherently disturbing that the world of equity investment has become so feral and unstable No wonder property investment takes pride of place in most peoples asset portfolio and no surprise that listings both sides of the Atlantic are decling and private equity growing exponentially.

[steeplejack] 05/9/2022 09:13

High PE stock.Not a day to put your head over the parapet.For all the platitudes re being brave when others are fearful etc,there's not much point fighting the poor sentiment afflicting equities.Will retain my weighting in Dechra but unlikely to add.Cash remains king and for all the observations that the value of cash is eroded by inflation,its really not worth fighting the negative trend.There's too much uncertainty to box clever.

[johnrxx99] 05/9/2022 08:25

They will have to really motor in the 2nd half to achieve forecasts.

[1jat] 02/9/2022 17:03

And the second deal is done….this one seems to have an immediate commercial logic…more US manufacturing product that can be pushed through dechra sales….
Should enhance the group benefit if the new drugs come through from the more speculative first buy.

[johnrxx99] 02/8/2022 11:18

I suspect general nerviness with China, throw the US into the mix and VIX goes up.

[steeplejack] 02/8/2022 10:16

Few profit takers on back of opportunity afforded by recent discounted placing i suspect.

[spyder] 02/8/2022 09:08

Anyone know what has rattled DPH this morning?

[prokartace] 22/7/2022 09:53

I agree it didn't need to be a big discount as proved by today's share price This is why I took the opportunity with open arms. Who can say no to an 8% handout

[johnrxx99] 22/7/2022 09:37

It was a gift - as they say at DCH "never look a gift horse in the mouth". :-)

[spyder] 22/7/2022 09:00

One happy side effect of this placing is that it puts a bit more distance between DCH and FTSE 100 relegation.

[steeplejack] 22/7/2022 08:11

I can understand why in these markets,but a discount of 8% for a placing of less than 5% new equity is large.A placing discount of 3% would have been sufficient.Added to holding at generous price.

[prokartace] 21/7/2022 09:18

I have used this opportunity to buy into the share via primary bid. Was a little shocked to get 100% allotment but happy enough.

[johnrxx99] 21/7/2022 08:57

However, the rest of the operation is doing well and referring to the GSK demerger, the market seems to prefer a R&D centric operation to sales of existing products.

As ever time will tell but I added following today's RNS

[melody9999] 20/7/2022 17:58

Hmmm - no comments on the placing. Looked interesting until I got to this para.

Piedmont is a research and development business with an active product pipeline and is expected to have minimal revenues in the first full year of ownership. Dechra expects to increase, with immediate effect, its Group R&D spend to accommodate the Piedmont development activities alongside its existing product development pipeline, raising R&D expenditure as a proportion of sales from the range of five to six per cent. to seven to eight per cent. in each of the next three years which would be in line with the average for its animal pharmaceutical peer group.

DCH BOD must be very confident on the long term prospects, but given the current market I'm not sure I want to wait until 2026 or beyond.

[johnrxx99] 18/7/2022 09:46

That's it, get if off your chest LOL